Skip to content
7885.T

TAKANO Co.,Ltd.

TAKANO Co.,Ltd. Q4 FY2025 earnings call

May 22, 2025 · fiscal period ended 2025-03

EPS · actual vs est

/

Revenue · actual vs est

/
Ask about this call

Summary

Generated 2025-05-22

Management highlights

  • Leadership Change

    • The company announced an upcoming planned CEO transition, effective after the June 2025 shareholders' meeting. The incumbent CEO will move to the role of Chairman, and Masao Takano will take over as the new Representative Director CEO.
  • Operational and New Product Highlights

    • Furniture (living-related segment): Launched two new eco-friendly products: pallo, which features replaceable seat and back cushions for extended product lifespan, and Protty, which incorporates factory offcuts as cushion material.
    • Exterior segment: Awning products are seeing growing adoption across public spaces (parks, road stations, tourist facilities, hotels, highway service areas) amid rising demand for shade due to climate change and growing popularity of outdoor living.
    • Industrial Equipment segment: The BOS series of optical solenoid shutters, the company's new product line, is the industry's smallest and lightest. It is primarily used in infrared security cameras and as a light control component for laser communications in space applications, with nearly all output exported mainly to the U.S. and Europe, with shipments growing gradually.
    • Healthcare segment: Continues to participate in industry events including Kids Festa Tokyo 2025 to collect user feedback for pediatric assistive product development, and holds strong market recognition.
    • Agri-business promotion office: Uses the company's proprietary red-flowered buckwheat variety Takane Ruby for agricultural-welfare collaboration projects and regional tourism promotion, supporting local community activation.
    • Capital expenditures: Totaled 827 million yen for the fiscal year, invested in production machinery for industrial equipment, evaluation testing equipment for inspection measurement, molding machines and solar power infrastructure for living-related equipment, and company-wide core system development.
    • Research and development: Totaled 642 million yen for the fiscal year. R&D focuses include: environmental response and new material development for living-related equipment, clinical test reagent shelf-life extension research, high-speed high-precision image processing and AI-based defect classification for inspection measurement equipment.
    • Strategic Direction (Inspection and Measurement segment): Management continues to shift the segment's business focus away from the declining FPD sector toward semiconductor and functional film inspection, while working to grow overseas sales. R&D strengthening is the core mid-term priority, with increased budget allocation and internal personnel reallocation to support semiconductor-related development. The company has already secured an order for glass-core package inspection equipment for advanced AI server semiconductor packaging, with several additional orders near completion, leveraging the company's existing glass handling and inspection expertise from the FPD sector.
View in transcript ↓

Segment performance

For the 2025 March full year (fiscal 2024):

  1. Overall consolidated sales: 23.969 billion yen, down year-over-year. Operating income: 451 million yen, also down year-over-year.
  2. Living-related Equipment: 12.775 billion yen in revenue, accounting for 53.3% of total consolidated revenue, and was the firm's largest segment. It performed well year-over-year.
  3. Inspection and Measurement Equipment: 5.979 billion yen in revenue, a 20.5% year-over-year decrease, contributing ~25% of total consolidated revenue. Segment operating income fell to 61 million yen from 266 million yen year-over-year. Within this segment: semiconductor business revenue held steady at ~2.5 billion yen, making up 50.3% of the segment's total revenue, while FPD (flat panel display) business revenue fell by ~1 billion yen year-over-year, driving the segment's overall decline. China and Taiwan region revenue for the segment dropped significantly due to concentrated FPD production in this region. The segment's end-of-period order backlog was nearly flat year-over-year at 5.497 billion yen.
  4. Industrial Equipment: 2.277 billion yen in revenue, contributing 9.5% of total consolidated revenue, and posted a year-over-year revenue decline due to the semiconductor industry downturn and weak export demand to China.
  5. Exterior, Machinery & Tools: Smaller remaining segments that round out the total consolidated revenue.
View in transcript ↓

Guidance

  • For the 2026 March full year (fiscal 2025), management guides for 4.3% year-over-year consolidated revenue growth to 25.0 billion yen.
  • Operating income is guided to 750 million yen, a 66% year-over-year increase, and ordinary income is guided to 850 million yen.
  • Annual dividend per share is maintained at 20 yen.
  • For the Inspection and Measurement segment, management guides full year revenue growth to 6.354 billion yen, targeting over 3.0 billion yen in semiconductor business revenue, which would approach the segment's historical high for semiconductor revenue.
  • The Inspection and Measurement segment targets full year orders in the range of 6.0 billion yen to 6.5 billion yen.
  • Management expects continued solid performance from the core living-related equipment segment, supported by evolving work style trends and new product development.
View in transcript ↓

Risks

  • Weak demand in the semiconductor industry, particularly in the mature automotive semiconductor segment, has negatively impacted current and near-term revenue for the Industrial and Inspection and Measurement segments.
  • Declining demand for FPD products has driven significant revenue declines in the Inspection and Measurement segment.
  • Trump administration tariffs on U.S. imports are being closely monitored; while U.S.-bound sales only account for 5.1% of total revenue, the exposure is concentrated in the high-priority semiconductor business. Management continues to exchange information with local U.S. agents to monitor the situation.
  • New semiconductor-related R&D and product development typically takes 2-3 years to deliver revenue, creating near-term margin pressure and lag between investment and revenue returns.
  • The clinical test reagent business still suffers from low brand recognition, limiting sales conversion despite growing customer inquiries.
View in transcript ↓

Q&A highlights

Q: Can existing LCD technology be used for PLP (panel-level package) applications? Will the business expand to standalone conveying equipment, and what is the sales outlook? / A: Existing LCD glass handling and inspection expertise is directly applicable to glass-core PLP packages, as most semiconductor companies lack experience handling large glass panels compared to the LCD industry. Takano's existing color unevenness inspection technology is also directly transferable. The company only plans to integrate conveying functions as part of complete inspection systems, and does not plan to pursue standalone conveying equipment business at this time.

Q: What is the development status of inspection equipment for perovskite solar cells, and what is the expected future sales scale? / A: Takano is currently coordinating inspection specifications with customers, and the project requires additional R&D to meet new performance requirements. It is still too early to provide a specific sales outlook, as the product is still in the collaborative development phase.

Q: Does the current slowdown in EV sales delay the recovery of Takano's automotive-related semiconductor business? / A: It is true that market conditions for automotive semiconductors are currently weak, and a large share of Takano's mature semiconductor exposure is tied to automotive power and discrete semiconductors. However, Takano's product portfolio serves a wide range of end applications beyond automotive EVs, so demand remains relatively resilient. The company is also expanding exposure to advanced semiconductors for AI servers to drive overall segment growth, and expects the business to return to growth as market conditions recover.

Q: How has the clinical test reagent business progressed since launch? / A: The business is progressing, though not yet considered robust. After launch, low brand recognition limited sales, as customers were unfamiliar with the new entrant. Takano has adjusted its go-to-market strategy, shifting from direct sales to expanded channel partnerships, and increased promotional activity at academic conferences and industry workshops. Inquiries have grown notably, and the business is currently trending in a positive direction as conversion improves.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS
Revenue

Transcript

May 22, 2025

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.